One of the implicit assumptions in melatonin therapy is that the amplitude of nocturnal pineal melatonin secretion decreases with age. Hence, some might suggest that melatonin therapy would be more useful to those over 55 (or some other arbitrary age) because it might replace a deficiency.
A second assumption is that melatonin's mechanism of action relevant to sleep consolidation is that it has a modest ability to entrain the endogenous circadian oscillator (in the hypothalamus) when given in high doses... hence, the recommendation that melatonin be taken during the desired "night-time" and be repeated at the same time for several days in a row. In that the circadian component of the sleep drive is likely affected by age, this might also lead some to suggest that melatonin therapy is more likely relevant to older individuals.
Dew, found multiple sustained release OTC melatonin preparations just with Google search. Any ideas how these might differ from the Israeli product? Regards, bp
News 
Market Data 
Discover 
AI
